{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:12:45Z","timestamp":1768893165560,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DP1DA054394"],"award-info":[{"award-number":["DP1DA054394"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01MH118233"],"award-info":[{"award-number":["R01MH118233"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite the benefits associated with longer buprenorphine treatment duration (i.e., &gt;180 days) (BTD) for opioid use disorder (OUD), retention remains poor. Research on the impact of co-occurring psychiatric issues on BTD has yielded mixed results. It is also unknown whether the genetic risk in the form of polygenic scores (PGS) for OUD and other comorbid conditions, including problematic alcohol use (PAU) are associated with BTD. We tested the association between somatic and psychiatric comorbidities and long BTD and determined whether PGS for OUD-related conditions was associated with BTD. The study included 6686 individuals with a buprenorphine prescription that lasted for less than 6 months (short-BTD) and 1282 individuals with a buprenorphine prescription that lasted for at least 6 months (long-BTD). Recorded diagnosis of substance addiction and disorders (Odds Ratio (95% CI)\u2009=\u200922.14 (21.88\u201322.41), <jats:italic>P<\/jats:italic>\u2009=\u20092.8\u2009\u00d7\u200910<jats:sup>\u2212116<\/jats:sup>), tobacco use disorder (OR (95% CI)\u2009=\u200923.4 (23.13\u201323.68), <jats:italic>P<\/jats:italic>\u2009=\u20094.5\u2009\u00d7\u200910<jats:sup>\u2212111<\/jats:sup>), and bipolar disorder (OR(95% CI)\u2009=\u20099.70 (9.48\u20139.92), <jats:italic>P<\/jats:italic>\u2009=\u20091.3\u2009\u00d7\u200910<jats:sup>\u221291<\/jats:sup>), among others, were associated with longer BTD. The PGS of OUD and several OUD co-morbid conditions were associated with any buprenorphine prescription. A higher PGS for OUD (OR per SD increase in PGS (95%CI)\u2009=\u20091.43(1.16\u20131.77), <jats:italic>P<\/jats:italic>\u2009=\u20090.0009), loneliness (OR(95% CI)\u2009=\u20091.39(1.13\u20131.72), <jats:italic>P<\/jats:italic>\u2009=\u20090.002), problematic alcohol use (OR(95%CI)\u2009=\u20091.47(1.19\u20131.83), <jats:italic>P<\/jats:italic>\u2009=\u20090.0004), and externalizing disorders (OR(95%CI)\u2009=\u20091.52(1.23 to 1.89), <jats:italic>P<\/jats:italic>\u2009=\u20090.0001) was significantly associated with long-BTD. Associations between BTD and the PGS of depression, chronic pain, nicotine dependence, cannabis use disorder, and bipolar disorder did not survive correction for multiple testing. Longer BTD is associated with diagnoses of psychiatric and somatic conditions in the EHR, as is the genetic score for OUD, loneliness, problematic alcohol use, and externalizing disorders.<\/jats:p>","DOI":"10.1038\/s41398-023-02713-x","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T09:02:25Z","timestamp":1704877345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medical and genetic correlates of long-term buprenorphine treatment in the electronic health records"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8855-7393","authenticated-orcid":false,"given":"Maria","family":"Niarchou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Sanchez-Roige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"India A.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Reese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Marcovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea K.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"2713_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jsat.2014.07.010","volume":"48","author":"BD Stein","year":"2015","unstructured":"Stein BD, Gordon AJ, Dick AW, Burns RM, Pacula RL, Farmer CM, et al. Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abus Treat. 2015;48:104\u201311.","journal-title":"J Subst Abus Treat"},{"key":"2713_CR2","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","volume":"361","author":"J Kakko","year":"2003","unstructured":"Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361:662\u20138.","journal-title":"Lancet"},{"key":"2713_CR3","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jsat.2009.05.003","volume":"37","author":"JM Soeffing","year":"2009","unstructured":"Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abus Treat. 2009;37:426\u201330.","journal-title":"J Subst Abus Treat"},{"key":"2713_CR4","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"key":"2713_CR5","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/add.13270","volume":"111","author":"WH Lo-Ciganic","year":"2016","unstructured":"Lo-Ciganic WH, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Cathers T, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016;111:892\u2013902.","journal-title":"Addiction"},{"key":"2713_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","volume":"177","author":"AR Williams","year":"2020","unstructured":"Williams AR, Samples H, Crystal S, Olfson M. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. Am J Psychiatry. 2020;177:117\u201324.","journal-title":"Am J Psychiatry"},{"key":"2713_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35:22\u201335.","journal-title":"J Addict Dis"},{"key":"2713_CR8","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","volume":"174","author":"JM Liebschutz","year":"2014","unstructured":"Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174:1369\u201376.","journal-title":"JAMA Intern Med"},{"key":"2713_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.09.017","volume":"181","author":"CB Simon","year":"2017","unstructured":"Simon CB, Tsui JI, Merrill JO, Adwell A, Tamru E, Klein JW. Linking patients with buprenorphine treatment in primary care: predictors of engagement. Drug Alcohol Depend. 2017;181:58\u201362.","journal-title":"Drug Alcohol Depend"},{"key":"2713_CR10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1176\/appi.ps.201700363","volume":"69","author":"A Manhapra","year":"2018","unstructured":"Manhapra A, Agbese E, Leslie DL, Rosenheck RA. Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatr Serv. 2018;69:768\u201376.","journal-title":"Psychiatr Serv"},{"key":"2713_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","volume":"95","author":"H Samples","year":"2018","unstructured":"Samples H, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95:9\u201317.","journal-title":"J Subst Abuse Treat"},{"key":"2713_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","volume":"74","author":"ZM Weinstein","year":"2017","unstructured":"Weinstein ZM, Kim HW, Cheng DM, Quinn E, Hui D, Labelle CT, et al. Long-term retention in Office Based Opioid Treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65\u201370.","journal-title":"J Subst Abuse Treat"},{"key":"2713_CR13","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/s41593-022-01160-z","volume":"25","author":"RL Kember","year":"2022","unstructured":"Kember RL, Vickers-Smith R, Xu H, Toikumo S, Niarchou M, Zhou H, et al. Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci with predominant effects in brain regions associated with addiction. Nature Neuroscience. 2022;25:1279\u201387.","journal-title":"Nature Neuroscience"},{"key":"2713_CR14","doi-asserted-by":"publisher","first-page":"e1008164","DOI":"10.1371\/journal.pgen.1008164","volume":"15","author":"KJA Johnston","year":"2019","unstructured":"Johnston KJA, Adams MJ, Nicholl BI, Ward J, Strawbridge RJ, Ferguson A, et al. Genome-wide association study of multisite chronic pain in UK Biobank. PLoS Genet. 2019;15:e1008164.","journal-title":"PLoS Genet"},{"key":"2713_CR15","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41593-020-0643-5","volume":"23","author":"H Zhou","year":"2020","unstructured":"Zhou H, Sealock JM, Sanchez-Roige S, Clarke TK, Levey DF, Cheng Z, et al. Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. Nat Neurosci. 2020;23:809\u201318.","journal-title":"Nat Neurosci"},{"key":"2713_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41593-018-0326-7","volume":"22","author":"DM Howard","year":"2019","unstructured":"Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22:343\u201352.","journal-title":"Nat Neurosci"},{"key":"2713_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04930-1","volume":"9","author":"FR Day","year":"2018","unstructured":"Day FR, Ong KK, Perry JRB. Elucidating the genetic basis of social interaction and isolation. Nat Commun. 2018;9:2457.","journal-title":"Nat Commun"},{"key":"2713_CR18","doi-asserted-by":"crossref","unstructured":"Linn\u00e9r RK, Mallard TT, Barr PB, Sanchez-Roige S, Madole JW, Driver MN, et al. Multivariate genomic analysis of 1.5 million people identifies genes related to addiction, antisocial behavior, and health. bioRxiv 2020:2020.2010.2016.342501.","DOI":"10.1101\/2020.10.16.342501"},{"key":"2713_CR19","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/S2215-0366(20)30339-4","volume":"7","author":"EC Johnson","year":"2020","unstructured":"Johnson EC, Demontis D, Thorgeirsson TE, Walters RK, Polimanti R, Hatoum AS, et al. A large-scale genome-wide association study meta-analysis of cannabis use disorder. Lancet Psychiatry. 2020;7:1032\u201345.","journal-title":"Lancet Psychiatry"},{"key":"2713_CR20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41588-019-0481-0","volume":"51","author":"K Watanabe","year":"2019","unstructured":"Watanabe K, Stringer S, Frei O, Mirkov MU, de Leeuw C, Polderman TJC, et al. A global overview of pleiotropy and genetic architecture in complex traits. Nat Genet. 2019;51:1339\u201348.","journal-title":"Nat Genet"},{"key":"2713_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41588-021-00857-4","volume":"53","author":"N Mullins","year":"2021","unstructured":"Mullins N, Forstner AJ, O\u2019Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet. 2021;53:817\u201329.","journal-title":"Nat Genet"},{"key":"2713_CR22","unstructured":"National Quality Forum. Opioids and opioid use disorder: quality measurement priorities. Washington, DC: National Quality Forum; 2020."},{"key":"2713_CR23","unstructured":"Geissb\u00fchler A, Giuse D, Grande J, Miller RA, Stead WW. The Vanderbilt patient-care information system. Paper presented at Proceedings of the AMIA Symposium 1998."},{"key":"2713_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/clpt.2008.89","volume":"84","author":"DM Roden","year":"2008","unstructured":"Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR, et al. Development of a large\u2010scale de\u2010identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008;84:362\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"2713_CR25","first-page":"12","volume":"1","author":"M Niarchou","year":"2021","unstructured":"Niarchou M, Lin GT, Lense MD, Gordon RL, Davis LK. Medical phenome of musicians: an investigation of health records collected on 9803 musically active individuals. Ann N Y Acad Sci. 2021;1:12.","journal-title":"Ann N Y Acad Sci"},{"key":"2713_CR26","doi-asserted-by":"crossref","unstructured":"Dennis J, Sealock J, Levinson RT, Farber-Eger E, Franco J, Fong S, et al. Genetic risk for major depressive disorder and loneliness in sex-specific associations with coronary artery disease. Mol Psychiatry 2019;26:1\u201311.","DOI":"10.1101\/512541"},{"key":"2713_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09718-5","volume":"10","author":"T Ge","year":"2019","unstructured":"Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019;10:1776.","journal-title":"Nat Commun"},{"key":"2713_CR28","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/bioinformatics\/btq126","volume":"26","author":"JC Denny","year":"2010","unstructured":"Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene\u2013disease associations. Bioinformatics. 2010;26:1205\u201310.","journal-title":"Bioinformatics"},{"key":"2713_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser YI, Saxon AJ, Huang D, Hasson AI, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109:79\u201387.","journal-title":"Addiction"},{"key":"2713_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/ajad.12896","volume":"28","author":"C Montalvo","year":"2019","unstructured":"Montalvo C, Stankiewicz B, Brochier A, Henderson DC, Borba CPC. Long-term retention in an outpatient behavioral health clinic with buprenorphine. Am J Addict. 2019;28:339\u201346.","journal-title":"Am J Addict"},{"key":"2713_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.drugalcdep.2003.11.017","volume":"75","author":"G Gerra","year":"2004","unstructured":"Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 2004;75:37\u201345.","journal-title":"Drug Alcohol Depend"},{"key":"2713_CR32","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/ajad.12414","volume":"25","author":"DE Marcovitz","year":"2016","unstructured":"Marcovitz DE, McHugh RK, Volpe J, Votaw V, Connery HS. Predictors of early dropout in outpatient buprenorphine\/naloxone treatment. Am J Addict. 2016;25:472\u20137.","journal-title":"Am J Addict"},{"key":"2713_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1176\/appi.ajp.2015.15070921","volume":"173","author":"M Fava","year":"2016","unstructured":"Fava M, Memisoglu A, Thase ME, Bodkin JA, Trivedi MH, de Somer M, et al. Opioid modulation with buprenorphine\/samidorphan as adjunctive treatment for inadequate response to antidepressants: a Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2016;173:499\u2013508.","journal-title":"Am J Psychiatry"},{"key":"2713_CR34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1176\/appi.ajp.2015.15040535","volume":"173","author":"Y Yovell","year":"2016","unstructured":"Yovell Y, Bar G, Mashiah M, Baruch Y, Briskman I, Asherov J, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a Randomized Controlled Trial. Am J Psychiatry. 2016;173:491\u20138.","journal-title":"Am J Psychiatry"},{"key":"2713_CR35","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1038\/npp.2016.38","volume":"41","author":"E Falcon","year":"2016","unstructured":"Falcon E, Browne CA, Leon RM, Fleites VC, Sweeney R, Kirby LG, et al. Antidepressant-like effects of buprenorphine are mediated by Kappa Opioid receptors. Neuropsychopharmacology. 2016;41:2344\u201351.","journal-title":"Neuropsychopharmacology"},{"key":"2713_CR36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/acer.13594","volume":"42","author":"K Witkiewitz","year":"2018","unstructured":"Witkiewitz K, Vowles KE. Alcohol and opioid use, co-use, and chronic pain in the context of the opioid epidemic: a critical review. Alcohol Clin Exp Res. 2018;42:478\u201388.","journal-title":"Alcohol Clin Exp Res"},{"key":"2713_CR37","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/AJP.0000000000000603","volume":"34","author":"MD Sullivan","year":"2018","unstructured":"Sullivan MD. Depression effects on long-term prescription opioid use, abuse, and addiction. Clin J Pain. 2018;34:878\u201384.","journal-title":"Clin J Pain"},{"key":"2713_CR38","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41380-018-0332-x","volume":"25","author":"OB Smeland","year":"2020","unstructured":"Smeland OB, Bahrami S, Frei O, Shadrin A, O\u2019Connell K, Savage J, et al. Genome-wide analysis reveals extensive genetic overlap between schizophrenia, bipolar disorder, and intelligence. Mol Psychiatry. 2020;25:844\u201353.","journal-title":"Mol Psychiatry"},{"key":"2713_CR39","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1038\/s41380-021-01335-3","volume":"26","author":"S Sanchez-Roige","year":"2021","unstructured":"Sanchez-Roige S, Fontanillas P, Jennings MV, Bianchi SB, Huang Y, Hatoum AS, et al. Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry. Mol Psychiatry. 2021;26:6209\u201317.","journal-title":"Mol Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02713-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02713-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02713-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T09:02:59Z","timestamp":1704877379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02713-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2713"],"URL":"https:\/\/doi.org\/10.1038\/s41398-023-02713-x","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}